Nanologica is attending the Drug Delivery to the Lungs conference (DDL) during Dec 9-11. The DDL is the premier conference and industry exhibition which is dedicated to pulmonary and nasal drug delivery. The focus is on providing a forum to present t recent developments in the field of inhalation therapy. Representing Nanologica is Prof. Adam Feiler, CTO.
The publication “Empty mesoporous silica particles significantly delay disease progression and extend survival in a mouse model of ALS” has been published in Nature Research Scientific Reports, Nov 26, 2020. The publication relates to Nanologica’s patent application “Porous particles for use in treatment, prevention and/or postponement of degeneration of neurons and glia” that became public on Oct. 15, and demonstrates how empty porous silica particles has the potential of delaying the disease progression and extending